DOCKET NO.: JJPR-0177/ORT1509-PCT PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Steven W. Sutton and

Timothy W. Lovenberg Confirmation No.: 6621
Application No.: 10/537,732 Group Art Unit: 1645

Filing Date: June 7, 2005 Examiner: Not Yet Assigned

For: METHOD FOR IDENTIFYING MODULATORS OF HUMAN OREXIN-2

RECEPTOR

DATE OF DEPOSIT: May 8, 2007

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

DOCKET NO.: JJPR-0177 / ORT1509-PCT - 2 -

PATENT

	before the mailing date of a first Office Action after the filing of request for							
	continued examination under § 1.114, no additional fee is required.							
	In accordance with § 1.97(c), this Information Disclosure Statement is being							
	filed after the period set forth in § 1.97(b) above but before the mailing date of							
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or							
	before an action that otherwise closes prosecution in the application, therefore:							
	Certification in Accordance with § 1.97(e) is attached; or							
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.							
	In accordance with § 1.97(d), this Information Disclosure Statement is being							
	filed after the mailing date of either a Final Action under § 1.113 or a Notice							
	of Allowance under § 1.311 but before, or simultaneously with, the payment							
	of the Issue Fee, therefore included are: Certification in Accordance with §							
	1.97(e); and the submission fee of $$180.00$ as set forth in $$1.17(p)$.							
\boxtimes	Copies of reference numbers 23 - 27 listed on the attached Form PTO-1449							
	are enclosed herewith.							
	Copies of reference numbers on the attached Form PTO 1449 are not							
	required to be submitted pursuant to 37 CFR § 1.98(a)(2)(ii).							
	Copies of references - are not being submitted because							
	they were previously cited by or submitted to the U.S. Patent and							
	Trademark Office in patent application number , filed for							
	which a claim for priority under 35 U.S.C. § 120 has been made in the							
	instant application.							
The relevance of those listed references which are not in the English language is as								
follows:								

10537732 - GAU: 1647

DOCKET NO.: LIPR-0177 / ORT1509-PCT - 3 -

PATENT

There are no listed references which are not in the English language.

The attached references identified on the 1449 form were cited in the European Search Report dated April 4, 2007 that was received in the corresponding European application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

Date: May 8, 2007

/Phillip A. Singer/ Phillip A. Singer Registration No. 40,176

WOODCOCK WASHBURN LLP Cira Centre 2929 Arch Street, 12th Floor Philadelphia, PA 19104-2891 Telephone: (215) 568-3100 Faesimile: (215) 568-3439

Sheet 1 of 1

Form PTO-1449 Modified					ket No. R-0177 / Г1509-РСТ	lication No. 37,732			
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)					Applicant Steven W. Sutton and Timothy W. Lovenberg				
U.S. Department of Commerce Patent and Trademark Office					Filing Date Group June 7, 2005 1645				
					firmation No. I				
		FORE	IGN PATI	ENT I	OCUMENTS				
Examiner				_			Translation		
Initial		Document No.	Date	_	Country		YES	NO	
/SLW/	23	WO 01/85693	11/15/01	PCT					
0	THE	 R DOCUMENTS (I	ncluding A	utho	r, Title, Date, Per	tinent	Pages, Etc.)	
/SLW/ 24 Gartlon, J.E. et al., "Role of OX ₁ and OX ₂ receptors in the motor activity respond the orexins," Society for Neuroscience Abstracts, 2001, 27(1), 848						response to			
/SLW/	25	Jaszberenyi, M. et al., "Effects of orexins on the hypothalamic-pituitary-adrenal system," <i>Journal of Neuroendocronology</i> , 2000 , <i>12</i> (12), 1174-1178							
/SLW/	26	Mignot, E. et al., "Sleeping with the hypothalamus: emerging therapeutic targets for sleep disorders," <i>Nature Neuroscience, Nature America, Inc.</i> , 2002 , <i>5 Suppl.</i> , 1071-1075							
/SLW/	/SLW/ Sakurai, T. et al., "Oxerins and oxerin receptors: A family of hypothalamic neuropeptides and G Protein-coupled receptors that regulate feeding behavriour," Cell, 1998, 92, 573-585								
EXAMINER /Sandra Wegert/					DATE CONSID	ERED	01/24/200	8	